他克莫司联合阿魏酸哌嗪对肾病综合征患儿肾功能及凝血功能的影响

doi:10.3760/cma.j.issn.1007-1245.2023.02.015

国际医药卫生导报 ›› 2023, Vol. 29 ›› Issue (2): 207-.DOI: 10.3760/cma.j.issn.1007-1245.2023.02.015

他克莫司联合阿魏酸哌嗪对肾病综合征患儿肾功能及凝血功能的影响

栾海燕¹ 田巧焕¹ 王聪²

¹聊城市第三人民医院儿科，聊城　252000；²山东省立医院儿科，济南　250021

出版日期:2023-01-15 发布日期:2023-01-30
通讯作者: 栾海燕，Email：mmm13869521318@163.com
基金资助:
山东省自然科学基金青年项目（ZR2021QH223）

Effects of tacrolimus combined with piperazine ferulate on renal function and blood coagulation in children with nephrotic syndrome

Luan Haiyan¹, Tian Qiaohuan¹, Wang Cong²

¹Department of Pediatrics, Liaocheng Third People's Hospital, Liaocheng 252000, China; ²Department of Pediatrics, Shandong Provincial Hospital, Jinan 250021, China

Online:2023-01-15 Published:2023-01-30
Contact: Luan Haiyan, Email: mmm13869521318@163.com
Supported by:
Youth Project of Natural Science Fund in Shandong (ZR2021QH223)

摘要/Abstract

摘要：

目的　探讨他克莫司联合阿魏酸哌嗪对肾病综合征（NS）患儿肾功能及凝血功能的影响。方法　选取聊城市第三人民医院2019年1月至2020年12月肾病内科收治的61例NS患儿为研究对象，随机数字表法分为对照组30例、研究组31例。对照组：男12例、女18例，年龄1～10（5.61±1.35）岁；研究组：男15例、女16例，年龄1～11（5.52±1.28）岁。对照组给予阿魏酸哌嗪治疗，研究组给予他克莫司联合阿魏酸哌嗪治疗。比较两组患儿临床疗效及治疗前后肾功能［血肌酐（Scr）、尿素氮（BUN）、24 h尿蛋白定量］、凝血功能［凝血酶原时间（PT）、纤维蛋白原（FIB）、D-二聚体（D-D）］、免疫功能［免疫球蛋白（Ig）A、IgG、IgM］、肾小管损伤指标［尿中性粒细胞明胶酶相关脂质运载蛋白（NGAL）、肾损伤因子（KIM-1）］水平及不良反应发生情况，组间比较采用独立样本t检验、χ²检验。结果　研究组总有效率为90.32%（28/31），高于对照组的70.00%（21/30），两组比较，差异有统计学意义（P<0.05）。治疗后，研究组24 h尿蛋白定量、Scr、BUN、FIB、D-D、NGAL、KIM-1水平低于对照组，PT、IgA、IgG、IgM高于对照组（均P<0.05）。研究组不良反应发生率为19.35%（6/31），与对照组的16.67%（5/30）比较，差异无统计学意义（P>0.05）。结论　他克莫司联合阿魏酸哌嗪治疗NS患儿疗效确切且安全性高，可改善肾功能、凝血功能，调节免疫功能，降低肾小管损伤指标的表达水平。

关键词:

肾病综合征, 他克莫司, 阿魏酸哌嗪, 肾功能, 凝血功能

Abstract:

Objective　To investigate the effects of tacrolimus combined with piperazine ferulate on renal function and coagulation in children with nephrotic syndrome (NS). Methods　Sixty-one children with NS admitted to Department of Nephrology, Liaocheng Third People's Hospital from January 2019 to December 2020 were selected for the study and divided into in a control group (30 cases) and a study group (31 cases) by the random number table method. There were 12 boys and 18 girls in the control group who were 1-10 (5.61±1.35) years old. There were 15 boys and 16 girls in the study group who were 1-11 (5.52±1.28) years old. The control group were treated with piperazine ferulate, and the study group with tacrolimus and piperazine ferulate. The clinical efficacies and renal function [blood creatinine (Scr), urea nitrogen (BUN), 24 h urine protein quantification], coagulation function [prothrombin time (PT), fibrinogen (FIB), D-dimer (D-D)], immune function [immunoglobulin A (IgA), immunoglobulin G (IgG), immunoglobulin M (IgM)], and renal tubular injury indicators [urinary neutrophil gelatinase-associated lipid transport protein (NGAL), kidney injury factor (KIM-1)] before and after the treatment and incidences of adverse reactions were compared between the two groups by independent-sample t test and χ² test. Results　The total effective rate in the study group was higher than that in the control group [90.32% (28/31) vs. 70.00% (21/30)], with a statistical difference (P<0.05). After the treatment, the levels of 24 h urine protein quantification, Scr, BUN, FIB, D-D, NGAL, and KIM-1 were lower and the PT and levels of IgA, IgG, and IgM were higher in the study group than in the control group (all P<0.05). There was no statistical difference in the incidence of adverse reactions between the study group and the control group [19.35% (6/31) vs. 16.67% (5/30); P>0.05]. Conclusion Tacrolimus combined with piperazine ferulate is effective and safe in treating children with NS and can improve their renal function and coagulation, regulate their immune function, and reduce the expression levels of renal tubular injury indicators.

Key words:

Nephrotic syndrome, Tacrolimus, Piperazine ferulate, Renal function, Coagulation

栾海燕田巧焕王聪.

他克莫司联合阿魏酸哌嗪对肾病综合征患儿肾功能及凝血功能的影响 [J]. 国际医药卫生导报, 2023, 29(2): 207-.

Luan Haiyan, Tian Qiaohuan, Wang Cong.

Effects of tacrolimus combined with piperazine ferulate on renal function and blood coagulation in children with nephrotic syndrome [J]. International Medicine and Health Guidance News, 2023, 29(2): 207-.

参考文献

[1] 陆玮,王丽娜,郝志宏,等.槐杞黄颗粒辅助治疗儿童原发性激素敏感型肾病综合征的疗效[J].国际医药卫生导报,2021,27(16):2509-2514.DOI:10.3760/cma.j.issn. 1007-1245.2021.16.020.
[2] 曲英慧,周海澜.环孢素治疗儿童肾病综合征的临床效果观察[J].国际医药卫生导报,2021,27(8):1210-1214.DOI:10.3760/cma.j.issn.1007-1245.2021.08.026.
[3] 李小梅,邓秀兰.左旋咪唑联合糖皮质激素治疗原发性肾病综合征患儿的疗效及对血清sPD-1 sPD-L1的影响[J].河北医学,2020,26(8):1286-1291.DOI:10.3969/j.issn. 1006-6233.2020.08.013.
[4] 朱文婧,卓宇苗,梁钊雄.阿魏酸哌嗪辅助治疗糖尿病肾病的效果及对患者肾功能、血液流变学指标的影响[J].海南医学,2020,31(7):835-837.DOI:10.3969/j.issn.1003-6350. 2020.07.006.
[5] 陈强,郑建国,代广,等.尿毒清颗粒联合他克莫司治疗肾病综合征的疗效观察[J].现代药物与临床,2021,36(11):2337-2341.DOI:10.7501/j.issn.1674-5515.2021.11.023.
[6] 刘艳玲,赵巍,王晶,等.他克莫司治疗肾病综合征临床疗效及其对T淋巴细胞亚群影响研究[J].中国现代应用药学,2021,38(9):1084-1088.DOI:10.13748/j.cnki.issn1007-7693.2021.09.012.
[7] 中华医学会儿科学分会肾脏学组.儿童激素敏感、复发/依赖肾病综合征诊治循证指南(2016)[J].中华儿科杂志,2017,55(10):729-734.DOI:10.3760/cma.j.issn. 0578-1310. 2017.10.003.
[8] 蒋春波,於佳炜,林静,等.肾炎1号方联合西药治疗肾病综合征疗效及对患者凝血指标、免疫功能的影响[J].陕西中医,2020,41(12):1743-1746.DOI:10.3969/j.issn. 1000-7369.2020.12.016.
[9] 鲁静,吴文先.金匮肾气丸对肾病综合征患儿外周血PBMC中TLR4/NLRP3表达的影响[J].中国中西医结合肾病杂志,2020,21(10):895-898.DOI:10.3969/j.issn. 1009-587X. 2020.10.014.
[10] Sachdeva S, Khan S, Davalos C, et al. Management of steroid-resistant nephrotic syndrome in children[J]. Cureus, 2021,13(11):e19363. DOI: 10.7759/cureus.19363.
[11] Lee HK, Jang YJ, Na SW, et al. Sinkihwan-gamibang ameliorates puromycin aminonucleoside-induced nephrotic syndrome[J]. Chin J Nat Med, 2022,20(3):177-184. DOI: 10.1016/S1875-5364(22)60142-0.
[12] 李智英,刘晓红,黄志君,等.自我效能在肾病综合征患儿照顾者自我护理能力与患儿服药依从性的中介效应[J].现代临床护理,2022,21(4):31-37.DOI:10.3969/j.issn.1671-8283.2022.04.005.
[13] Yang C, Yang W, Chen Y, et al. Improving renoprotective effects by adding piperazine ferulate and angiotensin receptor blocker in diabetic nephropathy: a meta-analysis of randomized controlled trials[J]. Int Urol Nephrol, 2022,54(2):299-307. DOI: 10.1007/s11255-021-02927-2.
[14] 黄小丽,曾密帆,许素云.阿魏酸哌嗪联合羟苯磺酸钙治疗糖尿病肾病的疗效及对血清炎症因子和氧化应激因子的影响[J].广西医学,2021,43(20):2415-2420.DOI:10.11675/j.issn.0253-4304.2021.20.07.
[15] 赵忭阶,李胜开.环磷酰胺、他克莫司分别与糖皮质激素联合应用治疗特发性膜性肾病的疗效对比观察[J].山东医药,2021,61(15):61-64.DOI:10.3969/j.issn. 1002-266X. 2021.15.015.
[16] 任悦,李杨,刘春燕,等.他克莫司在治疗重型再生障碍性贫血中的免疫调节作用[J].中华医学杂志,2021,101(24):1929-1934.DOI:10.3760/cma.j.cn112137- 20201228- 03484.
[17] 段瑞强,高慧丽,刘莹.重组人生长激素对原发性肾病综合征患儿血清胰岛素生长因子-1、骨保护素的影响[J].中国中西医结合肾病杂志,2021,22(12):1103-1105.DOI:10.3969/j.issn.1009-587X.2021.12.025.
[18] 李英琛,庄克生,隋志燕,等.健脾脱敏清络汤联合泼尼松片对肾病综合征型紫癜性肾炎患儿凝血功能及免疫功能的影响[J].现代中西医结合杂志,2020,29(32):3592-3596.DOI:10.3969/j.issn.1008-8849.2020.32.012.
[19] 韩伟,马青青,冯伟勋,等.原发性肾病综合征患者经他克莫司联合泼尼松治疗后肾功能指标、血脂水平变化及安全性观察[J].解放军医药杂志,2022,34(5):64-66.DOI:10.3969/j.issn.2095-140X.2022.05.021.
[20] 艾年年,李章晗,黎华茂.益气消肿饮合穴位埋线治疗肾病综合征顽固性水肿疗效及对肾小管损害标志物、炎性细胞因子的影响[J].现代中西医结合杂志,2020,29(33):3708-3711.DOI:10.3969/j.issn.1008-8849.2020.33.015.
[21] Fu R, Tajima S, Shigematsu T, et al. Establishment of an experimental rat model of tacrolimus-induced kidney injury accompanied by interstitial fibrosis[J]. Toxicol Lett, 2021,341:43-50. DOI: 10.1016/j.toxlet.2021.01.020.

他克莫司联合阿魏酸哌嗪对肾病综合征患儿肾功能及凝血功能的影响

Effects of tacrolimus combined with piperazine ferulate on renal function and blood coagulation in children with nephrotic syndrome

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 1

编辑推荐

Metrics